← Feed

$IBRX

4 theses
bullish 100%neutral 0%bearish 0%
Avg return (6m)
—
Win rate (6m)
— (0 resolved)
1d3d1w1m3m6m1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 15, 4:30 PM ET
$IBRXr/pennystocksDDbullish
u/Ad_Weekly · 218d agono track record yet

$IBRX (ImmunityBio) can become the next short-term rocket/long-term investment

ImmunityBio's Anktiva immunotherapy targets IL-15 to boost natural killer cells and has demonstrated clinical efficacy in bladder cancer with FDA approval. Upcoming catalysts include EMA approval, Q4 2025 earnings, and high short interest (38.8%), positioning the stock for both short-term gains from short covering and long-term upside as the company scales production and expands into lung cancer, glioblastoma, HIV, and other indications.

At post $6.93Now $8.14+17.5% since postedas of Sep 15, 4:30 PM ET
original post →
$IBRXr/pennystocksDDbullish
u/lulmagician · 243d agono track record yet
“stacking position for a few days, currently balls deep into this”

Did a thing - IBRX

IBRX is executing on ANKTIVA commercialization with $113M in 2025 revenue (700% YoY growth) and recent NSCLC approval in Saudi Arabia de-risks the solid tumor platform. Upcoming BCG-naïve trial completion (Q2 2026) could expand TAM by moving the drug to earlier treatment lines, driving further upside.

At post $6.21Now $8.14+31.1% since postedas of Sep 15, 4:30 PM ET
original post →
$IBRXr/pennystocksBullishbullish
u/Bailey-96 · 244d agono track record yet

IBRX (ImmunityBio) - Great squeeze potential

IBRX is poised for a short squeeze with ~40% short interest, only 10 days to cover, and a pipeline of positive catalysts (lung cancer data, Saudi FDA approval, glioblastoma and CAR-NK data). The company has strong fundamentals (424% YoY revenue growth, $257M cash) that support a breakout above $3.00.

At post $6.21Now $8.14+31.1% since postedas of Sep 15, 4:30 PM ET
original post →
$IBRXr/pennystocksStock Infobullish
u/Due-Papaya-6217 · 245d agono track record yet

$IBRX - Possibly the greatest squeeze candidate in r/pennystocks history

IBRX is a potential squeeze candidate due to a structural imbalance: 136% of the 89M-share free float is shorted while the company demonstrates positive pipeline progress (positive lung cancer drug results) and potential strategic partnerships with Saudi Arabia for upfront cash deals.

At post $6.21Now $8.14+31.1% since postedas of Sep 15, 4:30 PM ET
original post →

End of results.